Our History

Our History

​Innovation is at our core.  85年来,我们一直专注于挽救和维持生命,提高患者护理水平.

Don Baxter IV Bottles

​1930s: Our First Decade of Innovation

1931: Drs. Ralph Falk and Don Baxter launched the Don Baxter Intravenous Products Corporation, the first commercial manufacturer of prepared IV solutions.

Not long after our founding, we introduced the TRANSFUSO-VAC container for blood collection and storage, which made blood banking practical and allowed storage for up to 21 days. 

By the decade’s end, we changed our name to Baxter Laboratories, Inc. 并在伊利诺伊州格伦维尤的一个翻新的汽车展厅开设了我们的第一家制造工厂.

Twin-Coil Artificial Kidney

1940s – 1960s: Industry Breakthroughs

1941: We introduced the PLASMA-VAC 容器,这是第一次允许血浆从全血中分离出来储存.

1948: We launched an unbreakable plastic container for blood storage.

1950: Our second U.S. manufacturing facility opened in Cleveland, Mississippi. Two years later, we became the first U.S. 在我们收购海兰德实验室之后,公司生产商业化的人类血浆.

1954: We went international, opening an office in Belgium. Two years later, Dutch physician Willem Kolff developed the first “artificial kidney,” which was made from wood slats, orange juice cans and a cellophane membrane. 以他的工作为基础,我们在那年晚些时候生产了第一个商业化的透析系统.

1960: We introduced the first peritoneal dialysis (PD) solution. PD通过腹膜而不是外部透析器来过滤肾衰竭患者血液中的废物. A year later, we began trading on the New York Stock Exchange.

VIAFLEX IV container

1970s – 1990s: Expanding our Global Presence and Innovations

1970: We introduced VIAFLEX, the first flexible, plastic IV container. This medical breakthrough allowed infusions within a closed system, which reduced the chance for contamination.

1971: Our company joined the Fortune 500 list of the largest American corporations. 我们还在北卡罗来纳州开设了一家静脉注射解决方案制造工厂,这是我们迄今为止最大的工厂之一.

Our MINI-BAG plastic containers came on market in 1974, making ready-to-use premixed drugs available to hospitals. We moved to our current headquarters in Deerfield, Illinois, the next year.

Homechoice Automated PD systems

We launched several products in the 1980s, including the INFUSOR pump, which allowed patients to receive IV therapy in any setting.


1991: Our INTERLINK IV Access System launched, introducing the first “needleless” system for IV therapy.

1994: HOMECHOICE, our automated peritoneal dialysis (APD) system, launched. 我们还在新加坡开设了一家工厂,为亚洲市场生产腹膜透析溶液.

1998: 我们对大田制药产品部的收购使体育外围网站成为吸入麻醉剂的领导者.  That same year, 我们推出了第一个用于全肠外营养的三腔柔性容器,并获得了我们的批准 TISSEEL product, the first fibrin sealant in the U.S.   

V-LINK needleless connector

2000s: A New Millennium of Innovation

本世纪初,我们的一些核心产品获得了一系列监管许可,这是值得注意的. These included:

  • EXTRANEAL, a non-glucose-based PD solution;
  • ADVATE, 第一个血友病重组因子VIII浓缩物,在细胞培养中不添加任何人类或动物蛋白;
  • FLEXBUMIN, the first albumin in a flexible, plastic container; and
  • SEVOFLURANE, an inhaled anesthetic used in surgery.

2007: We introduced V-LINK, the first IV connector with an antimicrobial coating. A few years later, we received FDA clearance for ARTISS, 第一种商用的缓凝纤维蛋白密封剂,用于烧伤患者的皮肤移植.

HEMOPATCH resorbable collagen-based pad

2011体育外围网站创投成立并成为我们识别和资助医疗保健创新的新途径. We also acquired Baxa Corporation to enhance our pharmacy automation offerings.

2012我们收购了智能输液泵制造商Sigma和Synovis Life Technologies, Inc .., a leading microsurgery products company.

2013: We acquired GAMBRO AB, a global innovator in renal care. We also received European Union marketing approval for HEMOPATCH 密封止血钳,在各种手术情况下帮助控制出血.


2015我们剥离了生物科学业务,专注于医院、营养、肾脏和外科护理. We also launched AMIA with SHARESOURCE,  首个具有用户友好功能的APD系统,帮助指导终末期肾病患者通过家庭腹膜透析(PD)治疗, while keeping them remotely connected with their healthcare providers.

2016: In Europe, we launched NUMETA G13%E这是一种经批准用于早产儿的三室即用型肠外营养系统. Also, HDx enabled by our THERANOVA 终末期肾病患者是否有一种新的透析疗法. The THERANOVA dialyser features an innovative membrane, which provides an expanded haemodialysis therapy (HDx).

KAGUYA automated peritoneal dialysis (APD) system

2017: New versions of our FLOSEAL and TISSEEL haemostatic agents launched. We acquired Claris Injectables Limited, a generic injectable pharmaceutical company, 并宣布与领先机构开展新的研究和临床开发合作,包括 Mayo Clinic and Ramot at Tel Aviv University/Tel Aviv Sourasky Medical Center.

2018: Our KAGUYA APD system launched in Japan, reflecting local needs and demographics, and making it a viable treatment option for renal patients there.